Basic and Clinical Studies of Pazufloxacin on Infectious Enteritis Research Group of T-3761 on Infectious Enteritis (Manager; Shoichiro IRIMAJIRI)

Autor:	Hiroko SAGARA, Kouji YOSHIKAWA, Isao TOMIZAWA, Yoshihiko TAKIZAWA, Yoshiro NITTA, Takafumi TSUNODA, Hiroyuki FUKUDA, Tsuyoshi YAMAGUCHI, Gohta MASUDA, Masayoshi NEGISHI, Atsushi AJISAWA, Misako MURATA, Kenji OHNISHI, Shoichiro IRIMAJIRI, Mitsuo OBANA, Fumio MATSUMOTO, Takero IMAI, Iwao SAKURAI, Takayuki TAKAHASHI, Masamiki MORI, Yoshiki MIZUNO, Kohji KATOH, Shiro HOSODA, Tadao BAMBA, Masaya SASAKI, Kunio YOSHIKAWA, Shuichi HIROTANI, Takeshi OGASAWARA, Hitoshi SAKUMOTO, Yasunobu KOMAI, Hideo OOKUBO, Young Ki KIM, Shinobu NAKAJO, Hirozumi OBATA, Yoshihiro SAKAUE, Hideki YOSHIDA, Tetsushi GOTO, Tadakazu AISAKA, Motoko MIKAMI, Kazunori KAGAWA, Yatsuka IMAGAWA, Masafumi FUKUYAMA, Yoshio MATSUBARA, Makoto SAITO
Rok vydání:	1996
Předmět:	Shigellosis Salmonella business.industry General Medicine medicine.disease medicine.disease_cause Cholera Enteritis Microbiology chemistry.chemical_compound chemistry Vibrio cholerae Pazufloxacin Medicine Shigella business Feces
Zdroj:	Journal of the Japanese Association for Infectious Diseases. 70:60-72
ISSN:	1884-569X 0387-5911
Popis:	A clinical study was carried out on pazufloxacin (PZFX) in 137 patients including shigellosis, Salmonella enteritis, enteropathogenic Esherichia coli enteritis and cholera, and carriers of these pathogens. Antibacterial activity of PZFX against clinical isolates, fecal concentration of PZFX and effects of PZFX on fecal microflora were also investigated. The overall clinical efficacy rate was 97.2%. The bacteriological efficacy rates were 98.2% against Shigella spp., 81.8% against Salmonella spp., 50% against Vibrio cholerae O1, and 100% against E. coli, V. parahaemolyticus, Aeronomas spp., Plesionomas shigelloides and V. cholerae non-O1, respectively. Side effect (epigastralgia) was observed in 1 of 130 cases (0.8%). The rate of abnormal laboratory findings was 11.2% (11/98). These were mainly elevation of GOT and/or GPT and increased eosinophils. The clinical usefulness rate was 95.2%. The MIC90 values of PZFX against Shigella spp., Salmonella spp. and E. coli were 0.025, 0.025 and 0.025 micrograms/ml, respectively. The results of fecal drug concentration and the effects on fecal microflora in one patient were compatible with those obtained in healthy volunteers.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4c31c85459238dac2c0a38672e3d7933 https://doi.org/10.11150/kansenshogakuzasshi1970.70.60 Zobrazit plný text záznamu